Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research ArticlePharmacology Vignette

Dabigatran (Pradaxa)

J. Comin and D.F. Kallmes
American Journal of Neuroradiology March 2012, 33 (3) 426-428; DOI: https://doi.org/10.3174/ajnr.A3000
J. Comin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.F. Kallmes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

Summary: Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

ABBREVIATIONS:

aPTT
activated partial thromboplastin time
ECT
Ecarin clotting time
INR
international normalized ratio
pGP
P-glycoprotein
TT
thrombin clotting time

Thrombin catalyzes the conversion of factors V, VIII, and XI to their activated forms and the conversion of fibrinogen to fibrin and factor XIII to XIIIa (Fig 1).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

The central role of thrombin in clot formation.

Thrombin also activates transmembrane G-protein-coupled protease-activated receptors on the platelet cell membrane. Downstream signaling results in conformational change, in turn allowing platelet aggregation and release of more coagulation factors and generation of more thrombin (Fig 1). The multifactorial, central, and self-perpetuating role of thrombin in clot formation makes it an appealing theoretic target for the prevention of thrombosis.

Mechanism of Action

Dabigatran (Pradaxa) reversibly binds to the active site on the thrombin molecule, preventing thrombin-mediated activation of coagulation factors. It may have less of an antagonistic effect on thrombin-mediated platelet aggregation (see “Adverse Effects” section). Furthermore, Dabigatran can inactivate thrombin even when thrombin is fibrin-bound; it reduces thrombin-mediated inhibition of fibrinolysis and, therefore, may even enhance fibrinolysis (Fig 2).1

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Thrombin receptors. Dabigatran binds to the active site, independent of fibrin-binding, thereby reducing conversion of coagulation factors. Thrombin-mediated platelet aggregation is relatively less affected.

In contrast to direct thrombin inhibitors, warfarin (Coumadin, an “indirect” thrombin inhibitor) exerts its effect by reducing vitamin K–dependent synthesis of thrombin and of coagulation factors higher up the cascade. This results in a delayed onset of antithrombotic effect (already existent coagulation factors have half-lives of up to 3 days) and an initial prothrombotic effect (warfarin also inhibits synthesis of endogenous anticoagulants, which have far shorter half-lives); heparin (Lipo-Hepin and Liquaemin) usually has to be coadministered initially.

Clinical Indications

The indications for dabigatran are identical to those for warfarin: the prevention of arterial or venous thrombosis. Of interest to the neuroradiologist, the RE-LY trial compared dabigatran with warfarin in the setting of stroke prophylaxis for atrial fibrillation and showed it to be noninferior (at a dose of 110 mg twice daily) or superior (at 150 mg twice daily) in the prevention of ischemic stroke.2

Administration

Dabigatran etexilate is the bioavailable oral formulation and is converted by liver hydrolysis to the active form. It is not highly protein-bound in plasma, is not dependent on (highly genetically polymorphic) CYP P450 metabolism, and is formulated with tartaric acid to ensure reliable intestinal absorption independent of gastric pH. It, therefore, has generally predictable pharmacokinetics and dosing (in contrast to warfarin).

Time to maximal plasma concentration and maximal clinical effect is 2 hours or less.3 Plasma half-life is approximately 12 hours,4 and dosing is therefore twice daily. Clearance is predominantly (∼80%) renal,5 and the drug will accumulate in renal failure. Dosing modifications are straightforward given the linear metabolism.

Adverse Effects

As with all antithrombotic agents, the primary side effect is hemorrhage. The RE-LY trial demonstrated that dabigatran was associated with a lower incidence of major hemorrhage than warfarin; in particular, the incidence of hemorrhagic stroke was markedly reduced (P < .001).2

Furthermore, dabigatran has been shown to have no effect compared with a placebo on the volume of cerebral hematoma induced in mice; in comparison, mice pretreated with warfarin had significantly larger hematomas.6 This may be because dabigatran binds only to the active site on the thrombin molecule and not to the exosite involved in thrombin-mediated platelet aggregation. The relative preservation of this function with dabigatran compared with indirect thrombin inhibitors may explain the reduced incidence and volume of cerebral hematoma.7

RE-LY demonstrated dyspepsia as the most common reason for patients choosing to discontinue dabigatran.

Interactions

Dabigatran etexilate (but not its active metabolite) is a substrate for the pGP efflux transport system.8 There are numerous inhibitors (eg, ketoconazole, verapamil, amiodarone, quinidine) and inducers (eg, rifampin) of pGP. Many studies have been conducted demonstrating changes in cMax and area under the curve when these drugs are coadministered with dabigatran, but none have shown a significant effect on clotting function.9 There is not yet sufficient knowledge to allow the provision of strict guidelines for dose modification; these will undoubtedly emerge as experience with the drug increases.10

Measuring Response

Because of its predictable pharmacokinetics, dabigatran does not require routine close monitoring of clotting function, as warfarin does. If monitoring is required, prothrombin time/INR (a measure of extrinsic coagulation cascade) and aPTT (a measure of intrinsic coagulation cascade) are not quantitatively accurate for the effect of dabigatran on clotting function; these tests are instead replaced by TT and ECT.11

Reversal

In patients with normal renal function, dabigatran levels will fall to 25% of steady-state concentration after 24 hours and to 6.25% after 48 hours. Therefore, it may be reasonable to cease dabigatran 1 day before an elective procedure but earlier in higher-risk procedures (eg, spinal procedures, cardiac comorbidity, and so forth). The length of time the drug needs to be ceased obviously needs to be increased in patients with renal impairment, and aPTT/TT/ECT can be measured to ensure that they are within the normal range.

In the setting of bleeding complications or emergent surgery/procedures, no reversal agents have established efficacy in humans. Vitamin K and protamine are unlikely to have any significant effect. Hemodialysis/filtration is effective in rapidly reducing the concentration of the drug.

Economic Issues

Dabigatran twice daily costs approximately $13 per day,12 which far exceeds the cost of warfarin (probably <$1 per day). This does not, however, take into account the costs associated with INR monitoring; the overall Quality Adjusted Life Year costs are probably comparable.13

Summary

Dabigatran has a number of important advantages over warfarin and is likely to become increasingly frequently prescribed. Its potentially greater efficacy, simpler dosing, and better safety profile, particularly with regard to intracerebral hemorrhage, are all a direct result of its appealing pharmacokinetic and pharmacodynamic profiles. Its main comparative disadvantages relate to the monitoring of effect and reversal, and any proceduralist should be familiar with these.

View this table:
  • View inline
  • View popup

Warfarin vs dabigatran comparison

Footnotes

  • Disclosures: David F. Kallmes—UNRELATED: Grants/Grants Pending: MicroVention,* ev3*, Penumbra,* Micrus,* Payment for Lectures (including service on speakers bureaus): MicroVention,* Royalties: University of Virginia Patent Foundation; Payment for Development of Educational Presentations: ev3,* CareFusion,* Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: MicroVention.* *Money paid to the institution.

References

  1. 1.↵
    1. Ammollo C,
    2. Semeraro F,
    3. Incampo F,
    4. et al
    . Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8: 790– 98
    CrossRefPubMed
  2. 2.↵
    1. Connolly S,
    2. Ezekowitz M,
    3. Yusuf S,
    4. et al
    . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139– 51
    CrossRefPubMed
  3. 3.↵
    1. Stangier J,
    2. Rathgen K,
    3. Stahle H,
    4. et al
    . The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292– 303
    CrossRefPubMed
  4. 4.↵
    1. Stangier J,
    2. Stahle H,
    3. Rathgen K,
    4. et al
    . Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47– 59
    CrossRefPubMed
  5. 5.↵
    1. Stangier J,
    2. Rathgen K,
    3. Stahle H,
    4. et al
    . Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259– 68
    CrossRefPubMed
  6. 6.↵
    1. Lauer A,
    2. Cianchetti F,
    3. Van Cott E,
    4. et al
    . Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124: 1654– 62. Epub 2011 Sep 12.
    Abstract/FREE Full Text
  7. 7.↵
    1. Celikel R,
    2. McClintock R,
    3. Roberts J,
    4. et al
    . Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ib alpha. Science 2003; 301: 218– 21
    Abstract/FREE Full Text
  8. 8.↵
    1. Eriksson B,
    2. Quinlan D,
    3. Weitz J
    . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1– 22
    CrossRefPubMed
  9. 9.↵
    1. Liesenfeld K,
    2. Schafer H,
    3. Troconiz I,
    4. et al
    . Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527– 37
    CrossRefPubMed
  10. 10.↵
    Pradaxa [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals; 2003.
  11. 11.↵
    1. Van Ryn J,
    2. Stangier J,
    3. Naertter S,
    4. et al
    . Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor—interpretation of coagulation assays and reversal of anticoagulant activity. Thrombo Haemost 2010; 103: 1116– 27
    CrossRefPubMed
  12. 12.↵
    1. Flaker G,
    2. Weachter R
    . Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation. Curr Treat Options Cardiovasc Med 2011; 13: 361– 69
    CrossRefPubMed
  13. 13.↵
    1. Freeman J,
    2. Zhu R,
    3. Owens D,
    4. et al
    . Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1– 11. Epub 2010 Nov 1
    CrossRefPubMed
  • © 2012 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 33 (3)
American Journal of Neuroradiology
Vol. 33, Issue 3
1 Mar 2012
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dabigatran (Pradaxa)
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
J. Comin, D.F. Kallmes
Dabigatran (Pradaxa)
American Journal of Neuroradiology Mar 2012, 33 (3) 426-428; DOI: 10.3174/ajnr.A3000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Dabigatran (Pradaxa)
J. Comin, D.F. Kallmes
American Journal of Neuroradiology Mar 2012, 33 (3) 426-428; DOI: 10.3174/ajnr.A3000
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Summary
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref (15)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Antithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis
    Filippo Migliorini, Nicola Maffulli, Erlis Velaj, Andreas Bell, Daniel Kämmer, Frank Hildebrand, Ulf Krister Hofmann, Jörg Eschweiler
    Journal of Orthopaedics and Traumatology 2024 25 1
  • Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
    Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova, Regina F. Nasyrova
    Biomedicines 2021 9 5
  • Pharmacogenetics
    Natalia Shnayder, Marina Petrova, Elena Bochanova, Olga Zimnitskaya, Alina Savinova, Elena Pozhilenkova, Regina Nasyrova
    2021
  • Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis
    Filippo Migliorini, Nicola Maffulli, Erlis Velaj, Andreas Bell, Daniel Kämmer, Jörg Eschweiler, Ulf Krister Hofmann
    European Journal of Orthopaedic Surgery & Traumatology 2024 34 6
  • A Case of Liver Failure Due to Dabigatran Treated with Venovenous Hemodiafiltration and Idarucizumab
    Nicola Guglielmo, Daniele Orso, Rosalba Mestroni, Giulia Montanari
    Current Drug Safety 2020 15 3
  • Incidence and Prognostic Factors of Radial Artery Occlusion in Transradial Coronary Catheterization
    Matthaios Didagelos, Areti Pagiantza, Andreas S. Papazoglou, Dimitrios V. Moysidis, Dimitrios Petroglou, Stylianos Daios, Vasileios Anastasiou, Konstantinos C. Theodoropoulos, Antonios Kouparanis, Thomas Zegkos, Vasileios Kamperidis, George Kassimis, Antonios Ziakas
    Journal of Clinical Medicine 2024 13 11
  • Treating cancer-associated venous thromboembolism: A practical approach
    Eric Van Cutsem, Isabelle Mahé, Enriqueta Felip, Giancarlo Agnelli, Ahmad Awada, Alexander Cohen, Anna Falanga, Mario Mandala, Marc Peeters, Nikolaos Tsoukalas, Peter Verhamme, Cihan Ay
    European Journal of Cancer 2024 209
  • Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
    Xiaoping Xu, Qian Liang
    Clinical and Applied Thrombosis/Hemostasis 2019 25
  • Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet
    Naoto Ishikawa, Hanae Oshikiri, Shinya Takasaki, Masafumi Kikuchi, Taku Obara, Kazutoshi Akasaka, Masaki Matsuura, Hiroaki Yamaguchi, Nariyasu Mano
    Journal of Pharmaceutical Health Care and Sciences 2021 7 1
  • Latest advances in the reversal strategies for direct oral anticoagulants
    Jean Escal, Julien Lanoiselée, Géraldine Poenou, Paul Zufferey, Silvy Laporte, Patrick Mismetti, Xavier Delavenne
    Fundamental & Clinical Pharmacology 2024 38 4

More in this TOC Section

  • Clopidogrel (Plavix)
  • Trastuzumab (Herceptin)
Show more Pharmacology Vignette

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner
  • Book Reviews

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire